Evidence-based lifestyle modification platform for oncology achieves 90%+ adherence with new dedicated CoActive Coach model, significantly improving cancer-related health outcomes.NEW…
Dr. Ghosh is an interdisciplinary vision researcher with an interest in investigating the mechanisms underlying early diabetic retinopathy and age-related…
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells…
Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors…
Milestone Achieved as Adovate Initiates First-in-Human Study for Novel Asthma Therapy Targeting Underserved, Multi-Billion Dollar MarketGlen Allen, Va., May 13,…
Poster presentation to demonstrate EBT-107’s potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis…
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart DiseaseSOUTH SAN FRANCISCO, Calif., May…
SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel…
20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now…
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is…